SIGA to Present at the 8th Annual SVB Leerink Global Healthcare Conference on March 1, 2019
February 21 2019 - 7:30AM
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage
pharmaceutical company focused on the health security market, today
announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive
Officer, will present at the 8th Annual SVB Leerink Global
Healthcare Conference at 9:00 am ET on Friday, March 1, 2019 in New
York.
To access the live webcast and a copy of the
presentation, please visit the Investor Relations section of the
Company’s website, under Events & Presentations. A replay will
be available for a limited time following the presentation.
ABOUT SIGA TECHNOLOGIES,
INC. and TPOXX®
SIGA Technologies, Inc. is a commercial-stage
pharmaceutical company focused on the health security market.
Health security comprises countermeasures for biological, chemical,
radiological and nuclear attacks (biodefense market), vaccines and
therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX®, also known as tecovirimat
and ST-246®, an orally administered and IV formulation antiviral
drug for the treatment of human smallpox disease caused by variola
virus. TPOXX is a novel small-molecule drug of which 2 million oral
courses have been delivered to the Strategic National Stockpile
under Project BioShield. The oral formulation of TPOXX was approved
by the FDA for the treatment of smallpox on July 13, 2018. In
September 2018, SIGA signed a contract with the Biomedical Advanced
Research and Development Authority (BARDA) for procurement of oral
and intravenous formulations of TPOXX, and development activities.
For more information about SIGA, please visit www.siga.com.
ABOUT SMALLPOX1
Smallpox is a contagious, disfiguring and often
deadly disease that has affected humans for thousands of years.
Naturally-occurring smallpox was eradicated worldwide by 1980, the
result of an unprecedented global immunization campaign. Samples of
smallpox virus have been kept for research purposes. This has led
to concerns that smallpox could someday be used as a biological
warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine
vaccination for people at low risk of exposure to the smallpox
virus.
FORWARD-LOOKING STATEMENTS
This press release contains certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Such
forward-looking statements are subject to various known and unknown
risks and uncertainties, and SIGA cautions you that any
forward-looking information provided by or on behalf of SIGA is not
a guarantee of future performance. More detailed information about
SIGA and risk factors that may affect the realization of
forward-looking statements, including the forward-looking
statements in this press release, is set forth in SIGA's filings
with the Securities and Exchange Commission, including SIGA's
Annual Report on Form 10-K for the fiscal year ended December 31,
2017, and in other documents that SIGA has filed with the SEC. SIGA
urges investors and security holders to read those documents free
of charge at the SEC's web site at http://www.sec.gov. Interested
parties may also obtain those documents free of charge from SIGA.
Forward-looking statements are current only as of the date on which
such statements were made, and except for our ongoing obligations
under the United States of America federal securities laws, we
undertake no obligation to update publicly any forward-looking
statements whether as a result of new information, future events,
or otherwise.
Contacts:
Investors David Carey
212-867-1768 dcarey@lazarpartners.com
Media Stephanie
Seiler
206-713-0124 sseiler@lazarpartners.com
1
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Aug 2024 to Sep 2024
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Sep 2023 to Sep 2024